Diabetes mellitus is a chronic, metabolic, and complex disease that requires continuous treatment and medical care. Type 2 diabetes (T2DM) is disinfected by dysfunction of beta cells and insulin resistance. Gliptins are oral anti-hyperglycemic agents that control hyperglycemia. Acute pancreatitis (AP) is an acute inflammation that occurs in the pancreas. The correlation between acute pancreatitis and diabetes is complex, and there are many incorporated factors, such as anti-hyperglycemic drugs. The oresnt review aimed at providing an overview of acute pancreatitis and its association with T2DM, gliptins as a treatment for T2DM, and the correlation between AP and gliptins among T2DM patients. Scientific databases were used for searching for articles related to our subject. A variety of keywords were used for the search purpose, including “T2DM, AP, Association, Correlation, Incidence, Prevalence, Gliptin, dipeptidyl-peptidase-4 inhibitors.” Articles of relevance included those written in the English language, of any type, and conducted on the current subject. To cover as much of the current topic as possible, the discussion of the review contained three major sections. The first section covered acute pancreatitis and its connection to T2DM. In the second section, gliptin agents, safety, and negative effects were discussed. The third section discussed the correlation between acute pancreatitis and gliptin in T2DM patients. Acute pancreatitis was highly developed among type 2 diabetic patients; however, the correlation between acute pancreatitis and gliptins is controversial.
Key words: AP, gliptin, T2DM, correlation.
|
